Your browser doesn't support javascript.
loading
Complete Substrate Inhibition of Cytochrome P450 2C8 by AZD9496, an Oral Selective Estrogen Receptor Degrader.
Bapiro, Tashinga E; Sykes, Andy; Martin, Scott; Davies, Michael; Yates, James W T; Hoch, Matthias; Rollison, Helen E; Jones, Barry.
Afiliación
  • Bapiro TE; Oncology (T.E.B., A.S., S.M., M.D., J.W.T.Y., B.J.), Quantitative Clinical Pharmacology, Early Clinical Development (M.H.), and Drug Safety and Metabolism (H.E.R.), IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom tashinga.bapiro1@astrazeneca.com.
  • Sykes A; Oncology (T.E.B., A.S., S.M., M.D., J.W.T.Y., B.J.), Quantitative Clinical Pharmacology, Early Clinical Development (M.H.), and Drug Safety and Metabolism (H.E.R.), IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Martin S; Oncology (T.E.B., A.S., S.M., M.D., J.W.T.Y., B.J.), Quantitative Clinical Pharmacology, Early Clinical Development (M.H.), and Drug Safety and Metabolism (H.E.R.), IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Davies M; Oncology (T.E.B., A.S., S.M., M.D., J.W.T.Y., B.J.), Quantitative Clinical Pharmacology, Early Clinical Development (M.H.), and Drug Safety and Metabolism (H.E.R.), IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Yates JWT; Oncology (T.E.B., A.S., S.M., M.D., J.W.T.Y., B.J.), Quantitative Clinical Pharmacology, Early Clinical Development (M.H.), and Drug Safety and Metabolism (H.E.R.), IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Hoch M; Oncology (T.E.B., A.S., S.M., M.D., J.W.T.Y., B.J.), Quantitative Clinical Pharmacology, Early Clinical Development (M.H.), and Drug Safety and Metabolism (H.E.R.), IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Rollison HE; Oncology (T.E.B., A.S., S.M., M.D., J.W.T.Y., B.J.), Quantitative Clinical Pharmacology, Early Clinical Development (M.H.), and Drug Safety and Metabolism (H.E.R.), IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Jones B; Oncology (T.E.B., A.S., S.M., M.D., J.W.T.Y., B.J.), Quantitative Clinical Pharmacology, Early Clinical Development (M.H.), and Drug Safety and Metabolism (H.E.R.), IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
Drug Metab Dispos ; 46(9): 1268-1276, 2018 09.
Article en En | MEDLINE | ID: mdl-29921707
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Receptores de Estrógenos / Cinamatos / Inhibidores del Citocromo P-450 CYP2C8 / Indoles Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Receptores de Estrógenos / Cinamatos / Inhibidores del Citocromo P-450 CYP2C8 / Indoles Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido